Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura

American Journal of Hematology

Volumn 82, Issue 3, 2007, Pages 192-198

  Bussel, James B ^a   Hanna, Kim ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Idiopathic thrombocytopenic purpura; Intravenous immunoglobulin; Platelets; Safety; Tolerability

Indexed keywords

HUMAN IMMUNOGLOBULIN;

ABDOMINAL DISTENSION; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; ASTHMA; CHROMATOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GANGRENE; HEADACHE; HEMOLYSIS; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFUSION RATE; JOINT STIFFNESS; KIDNEY PAIN; MALE; MULTICENTER STUDY; NAUSEA; NEOPLASM; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; SORE THROAT; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING;

CAPRYLATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 33847656230     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20822     Document Type: Article

References (24)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for The American Society of Hematology. Blood 1996;88:3-40.
2. Cines D, Blanchette V. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
3. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-2554.
4. Cooper N, Woloski BM, Fodero EM, et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood 2002;99:1922-1927.
5. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenia purpura with high-dose dexamethasone. N Engl J Med 2003;349:831-836.
6. George JN, Raskob GE. Vesely SK, et al. Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003;74:161-169.
7. Souid AK. Sadowitz PD. Acute childhood immune thrombocytopenic purpura. Diagnosis and treatment. Clin Pediatr (Phila) 1995;34:487-494.
8. Woerner SJ, Abildgaard CF, French BN. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics 1981;67:453-460.
9. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-2251.
10. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous γ-globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-1231.
11. Bussel JB, Kimberly RP, Inman RD, et al. Intravenous γ-globulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983;62:480-486.
12. Bussel JB, Pham LC. Intravenous treatment with γ-globulin in adults with immune thrombocytopenic purpura: Review of the literature. Vox Sang 1987;52:206-211.
13. Carroll RR, Noyes WD, Rosse WF, Kitchens CS. Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. Am J Med 1984;76:181-186.
14. Oral A, Nusbacher J, Hill JB, Lewis JH. Intravenous γ-globulin in the treatment of chronic idiopathic thrombocytopenic purpura in adults. Am J Med 1984;76:187-192.
15. Warrier I, Lusher JM. Intravenous γ-globulin treatment for chronic idiopathic thrombocytopenic purpura in children. Am J Med 1984;76:193-198.
16. Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 1997;20:385-393.
17. Schiff RI, Sedlak D, Buckley RH. Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency. J Allergy Clin Immunol 1991;88:61-67.
18. Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: Evaluation of safety, efficacy, mechanisms of action and impact on quality of life. Thromb Haemost 2004;91:771-778.
19. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, Petteway SR Jr. Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma-derived intermediates. Biologicals 2002;30:153-162.
20. Lebing W, Remington KM, Schreiner C, Paul HI. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003;84:193-201.
21. Trejo SR, Hotta J, Lebing W, et al. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003;84:176-187.
22. Gelfand EW. Antibody-directed therapy: Past, present, and future. J Allergy Clin Immunol 2001;108:S111-S116.
23. Polmar SH, Smith TF, Pirofsky B, Rechtman D. Rapid infusion of intravenous immunoglobulin in patients with primary immunodeficiency disease. J Allergy Clin Immunol 1992;89:166.
24. Grillo JA, Gorson KC, Ropper AH, Lewis J, Weinstein R. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 2001;57:1699-1701.